Literature DB >> 6839959

Familial warfarin resistance.

R J Holt, C O Freytes.   

Abstract

Warfarin, a coumarin anticoagulant, acts by interfering with the hepatic synthesis of the vitamin-K-dependent clotting factors. It is used clinically in the treatment or prophylaxis of venous thrombosis and embolisms. Resistance to the effects of the coumarin and indanedione anticoagulants has been reported in rats and man, but its incidence has been defined as extremely rare. Resistance has been described as relative, acquired, or hereditary. The first well-documented case was also the first report to identify a genetic basis for this resistance. Since that time, there has been only one other study that strengthened the evidence for a hereditary transmission, and only a few other reports have suggested hereditary influence as a reason for coumarin resistance. In this report, a patient who presented with a familial-type warfarin resistance is described. A discussion of previous reports and possible mechanisms for nonfamilial warfarin resistance is also included.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839959     DOI: 10.1177/106002808301700409

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  Case studies in anticoagulation management.

Authors:  Wendy A Leong
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

2.  Bilateral femoral nerve compression by iliacus hematomas complicating anticoagulant therapy.

Authors:  Z A Jamjoom; A al-Bakry; A al-Momen; T Malabary; A R Tahan; B Yacub
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 3.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

4.  High clearance of (S)-warfarin in a warfarin-resistant subject.

Authors:  H O Hallak; P J Wedlund; M W Modi; I H Patel; G L Lewis; B Woodruff; A A Trowbridge
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.